Takeda Pharmaceutical Co. (TAK)
(Delayed Data from NYSE)
$13.36 USD
-0.13 (-0.96%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $13.35 -0.01 (-0.07%) 7:58 PM ET
5-Strong Sell of 5 5
A Value D Growth A Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TAK 13.36 -0.13(-0.96%)
Will TAK be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for TAK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TAK
FDA Expands argenx's (ARGX) Vyvgart Label to Treat Rare Disorder
OVID Slumps 76% on Epilepsy Drug Failing Two Pivotal Studies
TAK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Down -6.19% in 4 Weeks, Here's Why Takeda Pharmaceutical Co. (TAK) Looks Ripe for a Turnaround
Down -5.9% in 4 Weeks, Here's Why Takeda Pharmaceutical Co. (TAK) Looks Ripe for a Turnaround
All You Need to Know About Takeda Pharmaceutical Co. (TAK) Rating Upgrade to Strong Buy
Other News for TAK
Takeda's AI-Powered Strategy To Optimize Operations And Accelerate Its Pipeline
Big pharma rally after J&J earnings
3 Biotech Stocks For The Second Half Of 2024
Takeda Announces New Assignments of Directors
GLOBAL BRIEFING: Stocks to open higher after US tech stocks recover